The site you are about to enter is intended for US healthcare professionals.
Are you a US healthcare professional?
Confirm and enter Visit patient siteThe first and only silencer for ATTR-CM and hATTR-PN
Rapidly knocks down TTR
In a clinical study, AMVUTTRA® (vutrisiran) reduced TTR at 6 weeks after the first dose and maintained
reductions with continued treatment.
Results shown are from the ATTR-CM study. Similar reductions were seen in the hATTR-PN study (at 3 weeks after the first dose and with 1½ years of treatment).
Individual results may vary.
Reduces TTR at the source
As a silencer, AMVUTTRA suppresses TTR production in the liver—where most of it is made.
Important Safety Information
What are the most important things I should know about AMVUTTRA® (vutrisiran)?
AMVUTTRA can cause low vitamin A levels
Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.
Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.
What are the common side effects of AMVUTTRA?
The most common side effects of AMVUTTRA were pain in the arms or legs, pain in the joints, shortness of breath, and low vitamin A levels.
These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional information about AMVUTTRA, please see the full Prescribing Information.
Indications
What is AMVUTTRA?
AMVUTTRA is a prescription medicine that treats the:
- cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce heart-related death, hospital stays and urgent visits.
- polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Important Safety Information and Indications
Important Safety Information
What are the most important things I should know about AMVUTTRA® (vutrisiran)?
AMVUTTRA can cause low vitamin A levels
Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.
Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.
What are the common side effects of AMVUTTRA?
The most common side effects of AMVUTTRA were pain in the arms or legs, pain in the joints, shortness of breath, and low vitamin A levels.
These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional information about AMVUTTRA, please see the full Prescribing Information.
Indications
What is AMVUTTRA?
AMVUTTRA is a prescription medicine that treats the:
- cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce heart-related death, hospital stays and urgent visits.
- polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
cardiomyopathy of
ATTR amyloidosis
polyneuropathy of hereditary
ATTR amyloidosis
transthyretin
transthyretin-mediated
amyloidosis
Kansas City Cardiomyopathy
Questionnaire
6-minute walk test
modified Neuropathy
Impairment Score +7
Quality of Life-Diabetic
Neuropathy